CN105407906A - 预防或治疗巴斯综合征的方法和组合物 - Google Patents

预防或治疗巴斯综合征的方法和组合物 Download PDF

Info

Publication number
CN105407906A
CN105407906A CN201480022767.2A CN201480022767A CN105407906A CN 105407906 A CN105407906 A CN 105407906A CN 201480022767 A CN201480022767 A CN 201480022767A CN 105407906 A CN105407906 A CN 105407906A
Authority
CN
China
Prior art keywords
peptide
taz1
arg
phe
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480022767.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·特拉维斯·威尔逊
马克·班伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kant Biomedical Co ltd
Original Assignee
Stealth Peptides International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International Inc filed Critical Stealth Peptides International Inc
Priority to CN202211635437.3A priority Critical patent/CN115990242A/zh
Priority to CN202211634590.4A priority patent/CN115990241A/zh
Publication of CN105407906A publication Critical patent/CN105407906A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201480022767.2A 2013-03-01 2014-02-28 预防或治疗巴斯综合征的方法和组合物 Pending CN105407906A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202211635437.3A CN115990242A (zh) 2013-03-01 2014-02-28 预防或治疗巴斯综合征的方法和组合物
CN202211634590.4A CN115990241A (zh) 2013-03-01 2014-02-28 预防或治疗巴斯综合征的方法和组合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361771534P 2013-03-01 2013-03-01
US201361771642P 2013-03-01 2013-03-01
US61/771,534 2013-03-01
US61/771,642 2013-03-01
US201361839753P 2013-06-26 2013-06-26
US61/839,753 2013-06-26
PCT/US2014/019622 WO2014134554A1 (en) 2013-03-01 2014-02-28 Methods and compositions for the prevention or treatment of barth syndrome

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202211634590.4A Division CN115990241A (zh) 2013-03-01 2014-02-28 预防或治疗巴斯综合征的方法和组合物
CN202211635437.3A Division CN115990242A (zh) 2013-03-01 2014-02-28 预防或治疗巴斯综合征的方法和组合物

Publications (1)

Publication Number Publication Date
CN105407906A true CN105407906A (zh) 2016-03-16

Family

ID=51428869

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202211635437.3A Pending CN115990242A (zh) 2013-03-01 2014-02-28 预防或治疗巴斯综合征的方法和组合物
CN201480022767.2A Pending CN105407906A (zh) 2013-03-01 2014-02-28 预防或治疗巴斯综合征的方法和组合物
CN202211634590.4A Pending CN115990241A (zh) 2013-03-01 2014-02-28 预防或治疗巴斯综合征的方法和组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211635437.3A Pending CN115990242A (zh) 2013-03-01 2014-02-28 预防或治疗巴斯综合征的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211634590.4A Pending CN115990241A (zh) 2013-03-01 2014-02-28 预防或治疗巴斯综合征的方法和组合物

Country Status (9)

Country Link
US (5) US9687519B2 (enExample)
EP (2) EP2961420B1 (enExample)
JP (4) JP6518197B2 (enExample)
CN (3) CN115990242A (enExample)
CA (1) CA2916880C (enExample)
DK (1) DK2961420T3 (enExample)
ES (1) ES2750258T3 (enExample)
HU (1) HUE046924T2 (enExample)
WO (1) WO2014134554A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312066A (zh) * 2011-12-09 2017-11-03 康德生物医疗技术公司 芳香族阳离子肽及其用途
CN115990242A (zh) 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US9550981B2 (en) 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
WO2016094791A1 (en) * 2014-12-12 2016-06-16 University Of Washington Methods for treating and preventing cardiomyopathy
WO2018104172A1 (en) 2016-12-06 2018-06-14 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating barth syndrome
WO2018187400A1 (en) 2017-04-05 2018-10-11 Stealth Biotherapeutics Corp. Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
EP3898653A4 (en) * 2018-12-18 2022-08-24 Stealth BioTherapeutics Inc. ANALOGS TARGETING MITOCHONDRIAL DISEASES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129427A2 (en) * 2011-03-24 2012-09-27 Cornell University Aromatic-cationic peptides and uses of same

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
AU2002365425A1 (en) 2001-08-06 2003-09-02 Vanderbilt University An apparatus and methods for using biological material to discriminate an agent
BRPI0105509B8 (pt) 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
CN101440124B (zh) 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
AU2004210013A1 (en) * 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
WO2005023274A1 (en) 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CA3024434A1 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070265216A1 (en) * 2005-10-05 2007-11-15 Gross Richard W Enhanced medical treatment in diabetic cardiomyopathy
AU2007237899A1 (en) * 2006-04-18 2007-10-25 Cortendo Invest, Ab Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions
CA2688125A1 (en) 2007-05-02 2008-11-13 The Mclean Hospital Corporation Methods and compositions for mitochondrial replacement therapy
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
WO2008156654A2 (en) 2007-06-15 2008-12-24 Massachusetts Institute Of Technology Cytoskeleton modulators for treating metabolic disorders
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
WO2009149307A2 (en) 2008-06-04 2009-12-10 San Diego State University Research Foundation Compositions and methods for restoring mitochondrial electron transfer function
EA020091B1 (ru) 2008-08-07 2014-08-29 Ипсен Фарма С.А.С. Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
EP2419513A2 (en) 2009-04-17 2012-02-22 The Salk Institute For Biological Studies Regulation of aging by modulation of mitochondrial function
US20120046363A1 (en) 2009-05-11 2012-02-23 University Of Maryland, Baltimore Docosahexaenoic acid for the treatment of heart failure
CN105031605A (zh) 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
SMT202300433T1 (it) * 2009-08-24 2024-01-10 Stealth Biotherapeutics Inc Peptide per l'uso nella prevenzione o nel trattamento della degenerazione maculare
US20110082084A1 (en) 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
US8719939B2 (en) 2009-12-31 2014-05-06 Mcafee, Inc. Malware detection via reputation system
CA2786280A1 (en) 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP2519232A1 (en) 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
JP4643749B1 (ja) 2010-02-03 2011-03-02 昭和電工株式会社 表面被覆サーメット部材の耐酸化膜形成用の処理液
CA2790823A1 (en) 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
WO2011116007A1 (en) * 2010-03-15 2011-09-22 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
JP2013532124A (ja) 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
WO2012009171A2 (en) 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
MX2013001469A (es) 2010-08-06 2013-05-14 Edison Pharmaceuticals Inc Tratamiento de enfermedades mitocondriales con naftoquinonas
JP2013538799A (ja) 2010-08-06 2013-10-17 アンペア ライフ サイエンシーズ，インコーポレイテッド ビタミンｋを用いたミトコンドリア病の処置
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
CN106913860A (zh) 2011-09-29 2017-07-04 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
WO2013059071A1 (en) 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
CN104094119A (zh) * 2011-10-21 2014-10-08 斯特姆詹尼克斯公司 用于胞内传递生物活性分子的官能化纳米粒子
HK1204988A1 (en) 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CN104203262A (zh) * 2012-02-23 2014-12-10 康奈尔大学 芳香族阳离子肽及其用途
US20150266946A1 (en) 2012-10-09 2015-09-24 President And Fellows Of Harvard College Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function
WO2014066419A2 (en) * 2012-10-22 2014-05-01 Stealth Peptides International, Inc. Methods for reducing risks associated with heart failure and factors associated therewith
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
CN115990242A (zh) * 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
CA2916977A1 (en) * 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129427A2 (en) * 2011-03-24 2012-09-27 Cornell University Aromatic-cationic peptides and uses of same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DITI RONVELIA: "Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle", 《MOLECULAR GENETICS AND METABOLISM》 *
KATRIN BRANDNER: "Taz1, an Outer Mitochondrial Membrane Protein, Affects Stability and Assembly of Inner Membrane Protein Complexes: Implications for Barth Syndrome", 《MOLECULAR BIOLOGY OF THE CELL》 *
PHOON CK: "Tafazzin Knockdown in Mice Leads to a Developmental Cardiomyopathy With Early Diastolic Dysfunction Preceding Myocardial Noncompaction", 《JOURNAL OF AMERICAN HEART ASSOCIATION》 *
邹佳: "新型抗氧化肽SS31体外辐射防护作用及其机制的初步研究", 《辐射研究与辐射工艺学报》 *

Also Published As

Publication number Publication date
WO2014134554A1 (en) 2014-09-04
JP6918046B2 (ja) 2021-08-11
CA2916880C (en) 2021-02-09
US9687519B2 (en) 2017-06-27
US11083771B2 (en) 2021-08-10
EP2961420B1 (en) 2019-09-11
JP2016511259A (ja) 2016-04-14
ES2750258T3 (es) 2020-03-25
JP2019147815A (ja) 2019-09-05
JP2022116008A (ja) 2022-08-09
US12268724B2 (en) 2025-04-08
CA2916880A1 (en) 2014-09-04
DK2961420T3 (da) 2019-10-07
CN115990241A (zh) 2023-04-21
US20240156892A1 (en) 2024-05-16
JP7381652B2 (ja) 2023-11-15
US20210401923A1 (en) 2021-12-30
JP7072692B2 (ja) 2022-05-20
US11771734B2 (en) 2023-10-03
EP2961420A1 (en) 2016-01-06
HUE046924T2 (hu) 2020-03-30
US11083772B2 (en) 2021-08-10
US20200345803A1 (en) 2020-11-05
JP6518197B2 (ja) 2019-05-22
EP2961420A4 (en) 2016-08-17
EP3626252A1 (en) 2020-03-25
JP2021098704A (ja) 2021-07-01
CN115990242A (zh) 2023-04-21
US20160228487A1 (en) 2016-08-11
US20180147251A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
JP7072692B2 (ja) バース症候群の予防または治療のための方法及び組成物
CN102791280A (zh) 用于预防或治疗血管阻塞损伤的方法
US11266709B2 (en) Methods for the regulation of matrix metalloproteinase expression
EP4005582A1 (en) Treatment of left ventricular remodeling
US20200113966A1 (en) Methods and compositions for regulating srca2a expression levels in myocardial infarction
CN105579054A (zh) 预防或治疗左心室重塑的方法
HK40019493A (en) Methods and compositions for the prevention or treatment of barth syndrome
HK1219673A1 (en) Methods and compositions for the prevention or treatment of barth syndrome
HK1219673B (en) Methods and compositions for the prevention or treatment of barth syndrome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220627

Address after: Massachusetts, USA

Applicant after: Kant biomedical Co.,Ltd.

Address before: Monaco City, Monaco

Applicant before: STEALTH PEPTIDES INTERNATIONAL, Inc.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160316